Alphelix Biosciences
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Alphelix Biosciences - overview
Established
2025
Location
Suzhou, Jiangsu, China
Primary Industry
Biotechnology
About
Founded in 2025 and based in Suzhou, China, Suzhou Mingcheng Biotechnology Co. , Ltd. , dba Alphelix Biosciences, operates as a GPCR-focused early-stage drug discovery technology provider. The company develops integrated technology platforms to support early biomedical research and innovation.
In March 2026, Alphelix Biosciences raised Strategic Investment funding from Ming Bioventures. The company provides GPCR-related technology services through an integrated platform covering protein preparation, structural analysis, and functional antibody discovery. Its core platforms include MegaR, MegAb, and OmniCatchr, supporting GPCR structure biology and early drug discovery research. The company’s revenue is generated from GPCR-related technology services, research collaborations, and early-stage drug discovery support for pharmaceutical and biotechnology partners.
Current Investors
Ming Bioventures
Primary Industry
Biotechnology
Sub Industries
Biotechnology
Verticals
HealthTech
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.